Health Care Access & Coverage

Covering the Cure: Access and Payment for High-Cost Cell and Gene Therapies

A Conversation with Stacie Dusetzina, PhD, Titilope Fasipe, MD, PhD, Jarrod Henshaw, and Aaron Kesselheim, MD, JD, moderated by David Grande, MD, MPA

12:00p.m. – 1:00p.m. ET September 13, 2024 Virtual Event

New cell and gene therapies create the promise of curing debilitating conditions that were previously thought to be incurable. These highly specialized and highly personalized therapies come with price tags in the millions of dollars for a single treatment. For example, new treatments could cure sickle cell disease for some of the 100,000 Americans who live with the disease. However, the two approved treatments are between $2 and 3 million per dose. And projecting demand is challenging: some patients may be reluctant to undergo new treatment. How are public and private insurers thinking about paying for these therapies and how should they prepare for future breakthroughs? LDI’s expert panel will unpack the current landscape and options for increasing access to these treatments while creating sustainable payment strategies.


Stacie Dusetzina, PhD

Professor, Health Policy and Ingram Professor of Cancer Research, Vanderbilt University Medical Center

Titilope Fasipe, MD, PhD

Co-Director, Sickle Cell Program; Assistant Professor, Department of Pediatrics, Section of Hematology-Oncology, Baylor College of Medicine

Jarrod Henshaw

Senior Vice President, Chief Innovation and Supply Chain Officer, Prime Therapeutics

Aaron Kesselheim, MD, JD

Professor, Medicine, Harvard Medical School

David Grande

David Grande, MD, MPA (moderator)

Director of Policy, Leonard Davis Institute of Health Economics; Associate Professor of Medicine, Perelman School of Medicine